Assessment of Vitamin D Status in Male Osteoporosis

Al‐Oanzi, Ziad H.; Tuck, Stephen; Raj, N.; Harrop, J S; Summers, Gregory D.; Cook, David B.; Francis, Roger M.; Datta, Harish K.

doi:10.1373/clinchem.2005.059568

Cited by 51 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive association with 25(OH)D appeared stronger among men with a higher serum concentration of DBP, although the interaction was not formally statistically significant. Also, men with a higher 25(OH)D:DBP ratio, a proxy for free circulating 25(OH)D [34], [35], appeared to be at an increased risk of colorectal cancer, with stronger risk estimates for men with a serum DBP concentration above the median.…”

Section: Discussionmentioning

confidence: 98%

“…Kruskal-Wallis and chi-square tests were used to assess the statistical significance of differences across DBP quartiles. Conditional logistic regression was conducted to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CI) for the risk of colorectal cancer by quartile of 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, an estimation of free circulating 25(OH)D [34], [35]. Since 25(OH)D levels fluctuate throughout the year, season-specific quartiles of 25(OH)D were calculated based on the distribution of 25(OH)D in controls, split by season of blood draw during darker months (November-April) or sunnier months (May-October) and then merged into one variable.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Serum Vitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer

et al. 2014

View full text Add to dashboard Cite

BackgroundWe previously reported a positive association between serum 25-hydroxyvitamin D (25(OH)D) and colorectal cancer risk. To further elucidate this association, we examined the molar ratio of 25(OH)D to vitamin D binding protein (DBP), the primary 25(OH)D transport protein, and whether DBP modified the association between 25(OH)D and colorectal cancer risk.MethodsIn a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, controls were 1∶1 matched to 416 colorectal cancer cases based on age and date of blood collection. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) for quartiles of 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, a proxy for free, unbound circulating 25(OH)D.ResultsComparing highest to lowest quartiles, DBP was not associated with colorectal cancer risk (OR = 0.91; 95% CI: 0.58, 1.42, p for trend = 0.58); however, a positive risk association was observed for the molar ratio of 25(OH)D:DBP (OR = 1.44; 95% CI: 0.92, 2.26, p for trend = 0.04). In stratified analyses, the positive association between 25(OH)D and colorectal cancer was stronger among men with DBP levels above the median (OR = 1.89; 95% CI: 1.07, 3.36, p for trend = 0.01) than below the median (OR = 1.20; 95% CI: 0.68, 2.12, p for trend = 0.87), although the interaction was not statistically significant (p for interaction = 0.24).ConclusionCirculating DBP may influence the association between 25(OH)D and colorectal cancer in male smokers, with the suggestion of a stronger positive association in men with higher DBP concentrations. This finding should be examined in other populations, especially those that include women and non-smokers.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Methodsmentioning

confidence: 99%

Serum Vitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Survival time by 25(OH)D categories was estimated using the Kaplan–Meier method. Cox proportional hazards regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for lung cancer survival by quartiles of 25(OH)D, DBP, and the 25(OH)D:DBP molar ratio, a proxy for free circulating vitamin D (27, 28). Quartile cut-points were based on the distribution of 25(OH)D and DBP in all cases.…”

Section: Methodsmentioning

confidence: 99%

Serum vitamin D, vitamin D binding protein, and lung cancer survival

et al. 2014

View full text Add to dashboard Cite

Objectives Vitamin D may prolong cancer survival by inhibiting tumor progression and metastasis, however, there are limited epidemiologic studies regarding the association between circulating 25-hydroxyvitamin D (25(OH)D) and lung cancer survival. The aim of this study was to examine the relationship between serum 25(OH)D and lung cancer specific survival and to evaluate whether vitamin D binding protein (DBP) concentration modified this association. Materials and Methods 25(OH)D and DBP were measured in fasting serum samples from 500 male lung cancer cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for lung cancer related death according to quartiles of season-specific 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, a proxy for free circulating 25(OH)D. Results Comparing highest to lowest quartiles, serum 25(OH)D (HR=1.18; 95% CI: 0.89–1.56) and DBP (HR=0.95; 95% CI: 0.71–1.26) were not associated with lung cancer survival and DBP concentration did not modify the association with 25(OH)D (p for interaction=0.56). There was suggestion of an association between higher serum 25(OH)D and better survival from adenocarcinoma (HR=0.64; 95% CI: 0.17–2.45) and small cell carcinoma (HR=0.55; 95% CI: 0.21–1.45), but these estimates were based on a relatively small number of cases. Conclusion Serum 25(OH)D was not associated with overall lung cancer survival regardless of DBP concentration, however, these findings should be examined in other studies that include women and subjects with higher 25(OH)D levels.

show abstract

“…In elderly men with osteoporosis, serum 25 hydroxyvitamin D (25OHD) and intact parathyroid hormone (PTH) measurements may be used to exclude vitamin D insufficiency and secondary hyperparathyroidism (Aloanzi et al 2006). …”

Section: Investigation Of Osteoporosis In Menmentioning

confidence: 99%

Osteoporosis in the aging male: Treatment options

Tuck

Datta

2008

CIA

View full text Add to dashboard Cite

In elderly women, loss in bone mass and micro-architectural changes are generally attributed to the onset of menopause. Men do not experience menopause, they do, however, experience age-related acceleration in bone loss and micro-architecture deterioration. The incidence of osteoporotic fractures in elderly men, just as in aged women, increases exponentially with age; the rise in men, however, is some 5–10 years later than in women. Up to 50% of male osteoporotics have no identifiable etiology; however elderly males have much higher likelihood of having an identifiable secondary cause than younger men. Therefore, clinical and laboratory evaluation of aged male osteoporotics must be thorough and should be aimed at identifying lifestyle or conditions contributing to bone loss and fragility. It is essential to identify and treat secondary causes and ensure adequate vitamin D and calcium intake before embarking upon treatment with pharmacological agents. The evidence from a limited number of trials suggests that bisphosphonates, especially alendronate and risedronate, are effective in improving BMD, and seem to be the treatments of choice in aged men with osteoporosis. In cases where bisphosphonates are contra-indicated or ineffective, teriparatide or alternatives such as strontium should be considered.

show abstract

Assessment of Vitamin D Status in Male Osteoporosis

Cited by 51 publications

References 27 publications

Serum Vitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer

Serum Vitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer

Serum vitamin D, vitamin D binding protein, and lung cancer survival

Osteoporosis in the aging male: Treatment options

Contact Info

Product

Resources

About